Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead oral PDE4 inhibitor prodrug, PALI-2108, and related corporate and regulatory milestones. The company focuses on autoimmune, inflammatory, and fibrotic diseases, with particular emphasis on ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD).
News about Palisade Bio frequently highlights progress in its clinical programs. Recent announcements describe completion of Phase 1a and Phase 1b studies in UC, initiation and patient dosing in a Phase 1b study in FSCD, and plans to use these data to support Phase 2 IND submissions to the U.S. Food and Drug Administration. Company updates also discuss trial design elements such as safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory tissue-level and molecular analyses in intestinal biopsies and blood samples.
Investors and observers can also expect coverage of intellectual property developments, including composition-of-matter patents granted in Canada and Japan for PALI-2108 and related gut microbiota–activated PDE4 inhibitor prodrugs. Financing and capital markets activity is another recurring theme, with press releases detailing underwritten public offerings of common stock and common stock equivalents, as well as the intended use of proceeds to fund Phase 2 development in ulcerative colitis.
Additional Palisade Bio news items include participation in healthcare investor conferences, appointments of clinical and operational leaders with experience in gastroenterology and immunology, and governance matters such as stockholder meetings and special meeting outcomes. For readers following PALI, this news stream provides insight into the company’s clinical timelines, regulatory plans, patent estate, leadership, and financing decisions related to its gut-targeted PDE4 inhibitor prodrug platform.
Palisade Bio (Nasdaq: PALI) appointed Bram Verstockt, MD, PhD, to its Clinical Advisory Board to strengthen clinical and translational expertise for PALI-2108.
The company plans a Phase 2 ulcerative colitis IND submission in the first half of 2026 and aims to advance PALI-2108 in UC and fibrostenotic Crohn’s disease.
Palisade Bio (Nasdaq: PALI) announced a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM–1:55 PM ET. CEO JD Finley and President/CMO Dr. Mitchell Jones will present.
The event includes analyst-led discussions, one-on-one investor meetings for registered attendees, a live webcast on the company Events page at palisadebio.com, and a replay archived for a limited time.
Palisade Bio (Nasdaq: PALI) will present virtually at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The presentation runs 12:40 PM–1:10 PM ET in Track 3 and will be webcast live. Management will also hold one-on-one in-person meetings with qualified investors. A replay will be archived for a limited time on the company’s Investors Events page at palisadebio.com.
Palisade Bio (Nasdaq: PALI) appointed Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD to its Clinical Advisory Board to strengthen clinical strategy as PALI-2108 advances toward Phase 2 development. The company plans a Phase 2 UC IND submission in H1 2026 and focuses on targeted, once-daily oral PDE4 prodrugs for terminal ileum and colon delivery.
The advisors bring expertise in ulcerative colitis, Crohn’s disease, intestinal fibrosis, treat-to-target strategies, and late-stage trial design; Peyrin-Biroulet has authored >1200 peer-reviewed publications.
Palisade Bio (Nasdaq: PALI) announced two abstracts for its lead program PALI-2108 have been selected for poster presentations at major IBD meetings in early 2026. Presentations detail gut-targeted PDE4B inhibition and translational Phase 1a findings in ulcerative colitis.
Events and details: Crohn’s & Colitis Congress (Las Vegas) on Jan 23, 2026 — poster by James Izanec, MD; ECCO 2026 (Stockholm) on Feb 20, 2026 — poster P0989 by James Izanec, MD.
Palisade Bio (Nasdaq: PALI) announced a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation through its IBD Ventures program to support development of PALI-2108, a gut-microbiota-activated PDE4 inhibitor designed for targeted delivery to the terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC).
Palisade has completed Phase 1a single- and multiple-ascending dose and food-effect studies, plus a Phase 1b cohort in UC, and is conducting a Phase 1b cohort in FSCD. Data from these studies are expected to support Phase 2 IND submissions to the FDA in 2026.
Palisade Bio (NASDAQ: PALI) announced the Japan Patent Office granted a composition-of-matter patent for PALI-2108, a gut-microbiota-activated PDE4 B/D inhibitor targeting fibrostenotic Crohn’s disease (FSCD) and moderate-to-severe ulcerative colitis (UC).
The base patent term extends into 2041 and is eligible for patent term extension based on regulatory review timelines. PALI-2108 has completed Phase 1a SAD/MAD and FE studies, a Phase 1b cohort in UC, and is in an ongoing Phase 1b cohort in FSCD. Data are expected to support a Phase 2 IND submission in H1 2026. The patent expands the company’s global IP estate for its locally-acting PDE4 prodrug platform.
Palisade Bio (Nasdaq: PALI) appointed James Izanec, MD, AGAF as Vice President, Clinical Development effective Dec 2, 2025. Dr. Izanec is a physician‑scientist with over two decades of clinical and drug‑development leadership across immunology, neuroscience, and gastroenterology.
Key credentials cited: leadership of global Phase 2/3 programs including oversight of a 1,200‑patient Phase 3 Crohn’s program, strategic roles on ozanimod and deucravacitinib development, prior senior roles at Bristol Myers Squibb and Janssen, and principal‑investigator experience on more than 50 clinical trials.
Palisade Bio (Nasdaq: PALI) will present a live webcast fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:30 AM ET. CEO JD Finley and CMO Dr. Mitchell Jones will participate and management will be available for one-on-one in-person meetings with qualified, registered investors.
The webcast will be available on the company’s Investors > Events page at palisadebio.com, with a replay posted two hours after the live event and archived for 90 days.
Palisade Bio (NASDAQ: PALI) appointed Sharon Skare as Vice President, Global Head of Clinical Operations on Oct 28, 2025. Ms. Skare brings over 24 years of global clinical development and operations experience across autoimmune, metabolic, gastrointestinal, and fibrotic diseases.
The company is advancing PALI-2108, an orally administered, gut‑restricted prodrug designed to release a PDE4 inhibitor in the terminal ileum and colon. Palisade completed a Phase 1a/1b study with positive data, is conducting a Phase 1b study in fibrostenotic Crohn’s disease, and plans to submit Phase 2 INDs to the FDA in H1 2026. Management expects Skare’s experience in IBD operations and inspection readiness to support clinical and regulatory execution.